Literature DB >> 9495605

Immune markers in fibromyalgia: comparison with major depressed patients and normal volunteers.

S Bonaccorso1, A H Lin, R Verkerk, F Van Hunsel, I Libbrecht, S Scharpé, L DeClerck, M Biondi, A Janca, M Maes.   

Abstract

BACKGROUND: There is a high degree of comorbidity between fibromyalgia and major depression. The latter is characterized by signs of immune activation, whereas the immune status in fibromyalgia is not yet elucidated. The aims of the present study were to examine (i) neopterin and biopterin excretion in 24-h urine of patients with fibromyalgia compared with normal volunteers and patients with major depression; and (ii) the effects of subchronic treatment with sertraline (11 weeks) on the urinary excretion of neopterin and biopterin.
METHODS: Measurements of neopterin, biopterin, pseudouridine, creatinine and uric acid in 24-h urine were performed by means of HPLC in 14 fibromyalgia and ten major depressed patients and 17 normal volunteers.
RESULTS: There were no significant differences in urine excretion of the above five analytes between patients with fibromyalgia and normal volunteers. Patients with major depression showed significantly higher urinary neopterin excretion than normal volunteers and fibromyalgia patients. Patients with fibromyalgia and major depression had a significantly increased neopterin/creatinine ratio. Fibromyalgia patients had significantly lower urinary excretion of creatinine than patients with major depression. In fibromyalgia patients, there were no significant effects of sertraline treatment on any of the urine analytes.
CONCLUSIONS: The findings suggest that fibromyalgia, in contrast to major depression, may not be accompanied by activation of cell-mediated immunity. LIMITATION: Other immune markers should be measured in fibromyalgia before drawing definite conclusions. CLINICAL RELEVANCE: Increased urinary excretion of neopterin can be used as a marker for major depression, but not fibromyalgia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9495605     DOI: 10.1016/s0165-0327(97)00144-4

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  9 in total

Review 1.  Clinical staging in the pathophysiology of psychotic and affective disorders: facilitation of prognosis and treatment.

Authors:  Trevor Archer; Richard M Kostrzewa; Tomas Palomo; Richard J Beninger
Journal:  Neurotox Res       Date:  2010-03-17       Impact factor: 3.911

Review 2.  Inflammatory biomarkers and depression.

Authors:  Norbert Müller; Aye-Mu Myint; Markus J Schwarz
Journal:  Neurotox Res       Date:  2010-07-24       Impact factor: 3.911

Review 3.  Fibromyalgia and other unexplained clinical conditions.

Authors:  L A Aaron; D Buchwald
Journal:  Curr Rheumatol Rep       Date:  2001-04       Impact factor: 4.592

Review 4.  [Immunological aspects of depressive disorders].

Authors:  N Müller; M J Schwarz
Journal:  Nervenarzt       Date:  2007-11       Impact factor: 1.214

Review 5.  Status of immune mediators in fibromyalgia.

Authors:  Ali Gur; Pelin Oktayoglu
Journal:  Curr Pain Headache Rep       Date:  2008-06

6.  Normal production of inflammatory cytokines in chronic fatigue and fibromyalgia syndromes determined by intracellular cytokine staining in short-term cultured blood mononuclear cells.

Authors:  M R Amel Kashipaz; D Swinden; I Todd; R J Powell
Journal:  Clin Exp Immunol       Date:  2003-05       Impact factor: 4.330

Review 7.  A psychoneuroimmunological perspective to Emil Kraepelins dichotomy: schizophrenia and major depression as inflammatory CNS disorders.

Authors:  Norbert Müller; Markus J Schwarz
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-06       Impact factor: 5.270

8.  Epstein-Barr virus-encoded dUTPase enhances proinflammatory cytokine production by macrophages in contact with endothelial cells: evidence for depression-induced atherosclerotic risk.

Authors:  W James Waldman; Marshall V Williams; Stanley Lemeshow; Philip Binkley; Denis Guttridge; Janice K Kiecolt-Glaser; Deborah A Knight; Katherine J Ladner; Ronald Glaser
Journal:  Brain Behav Immun       Date:  2007-09-12       Impact factor: 7.217

Review 9.  The impact of neuroimmune dysregulation on neuroprotection and neurotoxicity in psychiatric disorders--relation to drug treatment.

Authors:  Norbert Müller; Aye-Mu Myint; Markus J Schwarz
Journal:  Dialogues Clin Neurosci       Date:  2009       Impact factor: 5.986

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.